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Abstract 
Background: Detection of tumor cells in the blood, or minimal deposits in distant organs as bone marrow, 
could be important to identify cancer patients at high risk of relapse or disease progression. Quantitative 
polymerase chain reaction (PCR) amplification of tissue or tumor selective mRNA is the most powerful tool 
for the detection of this circulating or occult metastatic cells. Our study aims to identify novel gastrointestinal 
cancer-specific markers for circulating tumor cell detection. Method: Phase I preclinical study was performed 
by means of computational tools for expression analysis. In silico data were used to identify and prioritize 
molecular markers highly expressed in gastrointestinal cancers but absent in hematopoietic-derived libraries. 
Selected genes were evaluated by means of qRT-PCR in gastrointestinal cancer and hematopoietic cell-lines, 
normal human bone marrows and bloods, tumor tissue, and blood from cancer patients. Results: Novel and 
known mRNA markers for circulating tumor cell detection in gastrointestinal cancer have been identified. 
Among all the genes assessed, PKP3, AGR2, S100A16, S100A6, LGALS4, and CLDN3 were selected and 
assays based on blood qRT-PCR were developed. Reliably qRT-PCR assays for the novel targets plakophilin 
3 (PKP3) and anterior gradient-2 (AGR2) to identify blood-borne cells in cancer patients were developed. 
Conclusions: Novel and known gastrointestinal-specific mRNA markers for circulating tumor cells have been 
identified through in silico analysis and validated in clinical material. qRT-PCR assay targeted to PKP3 and 
AGR2 mRNAs might be helpful to detect circulating tumor cells in patients with gastrointestinal cancer. 
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1. Introduction 
Cancer of the gastrointestinal (GI) system encompasses a great proportion of tumor-related 
deaths in the world. Stage at the time of diagnostic and suitability for curative surgery remains the 
most important prognostic factors for digestive tract tumors. However, distant and loco-regional 
relapses frequently occur in spite of resection and adjuvant therapy. Colorectal cancer is the 
second leading cause of cancer deaths in the western countries. Most of these patients are 
diagnosed with localized disease, but their average 5-year survival is 50–60% in European 
countries [1]. For patients with other common GI malignancies, the options for curative resections 
are limited and survival remains poor, especially for esophageal and gastric carcinomas and 
pancreatic cancer. 
 
Circulating tumor cells and occult metastasis (micrometastasis) are considered early stages in 
the progression of metastatic cascade in epithelial cancer. Detection of tumor cells in the blood or 
minimal deposits in distant organs as bone marrow could be important to identify patients at high 
risk of relapse or disease progression. 
 
PCR amplification of tissue or tumor-selective mRNA is the most powerful tool for detection 
of this circulating or occult metastatic cells. Cytokeratin 20, carcinoembryonic antigen (CEA), and 
epidermal growth factor receptor (EGFR) are among the most frequent mRNA markers used in 
different reverse-transcriptase polymerase-chain reaction (RT-PCR) assays in GI-cancer patients 
[2] ;  [3]. However, cancer genetic heterogeneity, down-regulation of mRNA marker in tumor 
cells, or low-level transcription of selected target in the hematopoietic compartment could 
compromise both sensitivity and specificity of molecular methods. 
 
Selection of novel gastrointestinal cancer-specific transcripts and development of multi-marker 
quantitative RT-PCR assays are clearly outstanding research questions [4] ;  [5]. 
 
EGFR has been found to be overexpressed in a high proportion of gastrointestinal cancer and 
confers a poor prognosis [6]. Development of a quantitative assay to detect EGFR-expressing 
circulating tumor cells could be relevant for prognostic assessment, monitor response, or even 
thought select target therapy [7]. 
 
RT-PCR assays for different glycosyltransferases have been developed for tumor cells 
detection in blood for breast cancer and melanoma patients [8]. Beta-1,6-N-
acetylglucosaminyltransferase V (GNT-V, MGAT5; Hs.200/Mm.161; EC 4.1.155) expression in 
colorectal cancer had been correlated with metastasis and poor prognosis [9]. Thus GNT-V could 
represent a suitable mRNA biomarker for circulating tumor cell detection in gastrointestinal cancer 
patients. 
 
The present study aims to identify novel GI cancer-specific markers for circulating tumor cells 
(CTC) detection. The development of mRNA-based tools for CTC biomarkers was done following 
the proposed guidelines of the Early Detection Research Network (EDRN) by the National Cancer 
Institute [10]. Phase I preclinical study was performed by means of computational tools for 
expression analysis. In order to validate the usefulness of this in silico approach to identify tumor 
cells markers, selected genes were evaluated in cell lines and clinical specimens. Finally, qRT-
PCR assays for the novel targets plakophilin 3 (PKP3) and anterior gradient-2 (AGR2) to identifiy 
blood-borne cells in cancer patients were developed. 
  
2. Materials and methods 
2.1. Digital differential display and computational tools 
Digital differential display (DDD) [11] is an in silico data-mining resource of the National 
Centre for Biotechnology Information (NCBI) for comparing sequence-based gene representation 
profiles. DDD is based on the UniGene concept and provides the genes that are represented at 
different levels in the selected cDNA libraries using statistical tests. DDD was used to identify 
molecular markers highly expressed in GI cancers but absent in blood and bone marrow-derived 
EST libraries. A set of cDNA libraries from blood and bone marrow (n = 13) was selected and it 
was compared with three pools of colon (n = 10), gastric (n = 13), and pancreatic (n = 5) 
carcinoma cDNA libraries. Each set was selected to include the broad heterogeneity of every 
tumor type and includes the minimum possible number of libraries generated from normalized or 
subtracted cDNAs. 
 
Tags with statistically significant (p < 0.05; Fisher's exact test) higher expression in GI cancer 
libraries were detected and each EST was identified by UniGene cluster. 
 
ESTs whose expression was 10 or more times higher in each set of cancer libraries in 
comparison with blood and bone marrow-derived EST libraries were selected. As a second filter 
step, we selected those tags with undetectable or low representation in hematopoietic control 
libraries, defined as an expression count equal or less than four in DDD output. 
 
Furthermore, the tissue distribution and tumor specificity of every gene selected were analyzed 
using representation profiles obtained with virtual northern blot [VN, Ref. [12]]. For each 
combination of tissue and pathologic status, VN shows a spot image representing the expression 
level of the selected gene and numeric columns. These represent the number of ESTs or SAGE 
tags corresponding to the gene divided by the total number of ESTs or SAGE tags in all libraries 
with the given tissue/histology. The statistical significance of the observed counts is measured 
using Bayesian analysis. Values (p) less or equal to 0.05 were considered significant [13]. Virtual 
northern blots for EGFR [14] and GNT-V [15] were also obtained. Functional data about the 
different gene selected were extracted from Gene Ontology (GO) annotations accessed in the 
Cancer Gene Anatomy Project (CGAP) database [12] ;  [16]. 
2.2. Cell lines 
As a surrogated model of gastrointestinal cancer, the following human tumor cell-lines were 
used: colorectal carcinoma Gp5d, LoVo, DLD1, LS513, HT29, OJC4, OJC5, OJC6; gastric 
adenocarcinoma OE19, and pancreatic carcinoma OJC1. In addition, hematopoietic cell lines 
Jurkat, KG1, and K562 were analyzed. 
 
The cell-lines OJC1, OJC4, OJC5, and OJC6 were developed in our laboratory from clinical 
specimens and they have been fully characterized [17]. All the cell lines were maintained in 
DMEM (Dulbecco's modified Eagle's medium-high glucose) and MegaCell™ RPMI-1640 
mediums (both provided by Sigma–Aldrich) supplemented with 10% fetal calf serum inactivated, 
1% penicillin, 1% streptomycin, and 1% amphotericin at 37 °C in 5% CO2. Cells from adherent 
cultures were recovered with 1% trypsin–1% EDTA cell dissociating reagent. Cell pellets from 
suspension cultures were obtained. 
  
2.3. Clinical tissue specimens and blood preparation 
Formalin-fixed and paraffin-embedded tissue (FFPE) from colon cancer specimens (n = 16) 
were obtained from the Pathology Department of the Juan Canalejo University Hospital. Array 
tissue apparatus, provided by Durviz, was used to obtain tissue cores with 2 mm diameter, 
selecting an area enriched for tumor tissue. These FFPE cores were used for specific mRNA 
detection of gene selected using DDD and computational tools. 
 
Blood samples were prospectively collected from an additional cohort of gastrointestinal 
carcinoma patients (n = 11) and from age and sex matched non-carcinoma donors (n = 10). All the 
patients included were in the advanced stage, including eight colorectal cancer stage IV, one stage 
III rectal cancer before any treatment, and two pancreatic adenocarcinomas (stages II and IV). 
Blood were collected in 10 ml EDTA-containing tubes. To eliminate skin-plug contamination of 
the blood sample from initial venipuncture, the first several milliliters of blood were discarded. 
Samples were subjected to lysis and stabilized, in less than 1 h after blood withdrawal, in 
guanidinium-based RNA/DNA stabilization reagent for blood/bone marrow (Roche, Mannheim, 
Germany) at 10% (v/v) without cell and plasma separation. The mixtures were stored at −80 °C 
until mRNA extraction. Isolation reagent for blood and bone marrow (Roche, Mannheim, 
Germany) was used for mRNA extraction. 
 
The study was approved by the Institutional Review Board of the Ethic Committee of Clinical 
Investigation of Galicia (Spain) and written informed consent was obtained from all patients. 
2.4. RNA extraction and qRT-PCR 
Isolation of total RNA from cell cultures was performed using High Pure RNA Isolation Kit 
(Roche, Mannheim, Germany) following manufacturer's instructions. From each cell line at 70% 
confluence, 10
6
 cells were obtained for RNA isolation. Total RNA was treated with DNase I. 
 
RNA isolation from FFPE tissue cores of each specimen was performed with Optimum™ 
FFPE RNA Isolation Kit (Ambion, Diagnostics); manufacturer's protocol was followed. 
 
RNA isolated from human normal bone marrows were purchased from BD Biosciences-
Clontech. Total RNA was derived from three different pools of normal human bone marrows 
(n = 23). 
 
mRNA isolation from blood samples was performed with mRNA Isolation Kit for Blood/Bone 
Marrow (Roche, Mannheim, Germany), following manufacturer's recommendations. Briefly, total 
nucleic acid fraction was adsorbed to magnetic glass particle and poly(A)+ RNA was captured by 
using biotin-labeled oligo(dT) and streptavidin-coated magnetic particles. Each mRNA preparation 
was eluted in 12 μl RNase-free redistilled water. Purified poly (A)+ RNA was further processed in 
RT-PCR or stored at −80 °C until use. RNA integrity was confirmed by 2% agarose gel 
electrophoresis and stained with ethidium bromide. 
2.5. cDNA synthesis 
Reverse-transcription (RT) was performed from total cellular and bone marrow RNA using 
SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen™, USA) up to a total 
volume of 20 μl × 1 μg of total RNA, 2.5 nM random hexamers, 0.5 mM dNTP mix, and 3 μl of 
DEPC-treated water were denatured at 65 °C for 5 min and chilled on ice for at least 1 min. On the 
other hand, 2 μl of 10× RT buffer, 5 mM MgCl2, 0.01 M DTT, and 40 U of RNaseOUT 
Recombinant Ribonuclease Inhibitor were mixed, collected by centrifugation, and incubated at 
25 °C for 2 min. After incubation, 50 U of SuperScript™ RT) were added and incubated at 25 °C 
for 10 min, 42 °C for 50 min, and 70 °C for 15 min in a Thermocycler (Gene Amp PCR System 
9700, Applied Biosystem). Finally, samples were chilled on ice and incubated with 2 U of RNAse 
H for 20 min at 37 °C before proceeding to amplification the target cDNA. For mRNA obtained 
from blood we follow the same procedure and 0.02 μg were subjected to cDNA synthesis. Positive 
and negative controls were included in each experiment. RNA extraction, reverse transcription-
PCR assay setup, and post-reverse transcription-PCR product analysis were carried out in separate 
designated rooms to prevent cross-contamination. cDNA was quantified and assessed for purity 
using a GENIOUS UV spectrophotometer. cDNA concentration was measured at 260 nm. Also 
A260/A280 relation was calculated to know cDNA quality. 
2.6. Quantitative real-time reverse transcription-PCR analysis 
Real-time PCR analysis was performed, using primers and conditions shown in Table 1, on 
LightCycler
®
 480 Instrument (Roche, Mannheim, Germany) using LightCycler 480 SYBR Green I 
Master (Roche, Mannheim, Germany). PCR reaction consisted of 10 μl of Master Mix 2× conc., 
0.35 μM of each forward and reverse primer, template cDNA and PCR-grade water up to a final 
volume of 20 μl in the LightCycler 480 Multiwell Plate 96. Multiwell Plate was centrifuged at 
3000 rpm for 2 min and was loaded in the LightCycler 480 Instrument until the PCR program 
started. An initial activation at 95 °C for 5 min was followed by an amplification target sequence 
50 cycles of 95 °C for 10 s, 54–60 °C (depending on the primers pair used) for 10 s, and 72 °C 
(depending on the amplicon size amplified) were used. For melting curve analysis 1 cycle of 95 °C 
for 5 s, 70 °C for 15 s, and 95 °C for 1 s was used. Finally, a cooling step was used at 40 °C for 
10 s. 
  
Table 1. qRT-PCR—primers and conditions: primers sequences, conditions and annealing temperature of real-time 
quantitative RT-PCR used to amplify selected genes 
Primers Sequence Length (mer) %GC Annealing temperature (°C) 
     
PKP3 1R 5′-ggatgaaaggttccacagga-3′ 20 50 60 
PKP3 2F 5′-ggcccgcagccttcaggccgtgcc-3′ 24 79 
GNT-V 1F 5′-att ggc aag cca act ctg a-3′ 19 47 55 
GNT-V 1R 5′-ttg agg tca aca gtc cac aca-3′ 21 48 
AGR2 2F 5′-ctg gcc aga gat acc aca gtc-3′ 21 57 54 
AGR2 2R 5′-agt tgg tca ccc caa cct-3′ 19 58 
S100A16 2F 5′-tgg aga gga ggc aga ctg ag-3′ 20 60 54 
S100A16 2R 5′-cca cca gga caa tga ctg c-3′ 19 58 
LGALS4 1F 5′-aac ctt caa ccc gcc tgt-3′ 18 56 54 
LGALS4 1R 5′-gag ccc acc ttg aag ttg at-3′ 20 50 
LCN2 1F 5′-cag gac tcc acc tca gac ct-3′ 20 60 54 
LCN2 1R 5′-cac ata cca ctt ccc ctg ga-3′ 20 55 
MGC3047 1F 5′-cca gaa gtc ggg aaa gtc aa-3′ 20 50 54 
MGC3047 1R 5′-ctc act cct gta aag cat ctg g-3′ 22 50 
EFNB1 1F 5′-tca tga agg ttg ggc aag a-3′ 19 47 54 
EFNB1 1R 5′-gtg tgg cca tct tga cag tg-3′ 20 55 
ASS 1F 5′-aag ctt ggg gcc aaa aag-3′ 18 50 54 
ASS1R 5′-gta gcg gtc ctc ata cag tgc-3′ 21 57 
CLDN3 2F 5′-cca tta tcc ggg act tct aca ac-3′ 23 48 60 
CLDN3 2R 5′-gac acg agc agc aga gca-3′ 18 61 
EGFR 2F 5′-cag cca ccc ata tgt acc atc-3′ 21 52 60 
EGFR 2R 5′-aac ttt ggg cga cta tct gc-3′ 20 50 
S100A6 2F 5′-act gcg aca cag ccc atc-3′ 18 61 60 
S100A6 2R 5′-gaa gat ggc cac gag gag-3′ 18 61 
HPRT 1F 5′-tga cct tga ttt att ttg cat acc-3′ 24 33 60 
HPRT 1R 5′-cga gca aga cgt tca gtc ct-3′ 20 55 
     
 
We verified that amplifications and the expected size of each PCR product were specific. 1.8% 
agarose gel electrophoresis of all PCR products revealed a single band that corresponded to the 
single-amplified products as predicted by the melting curve analysis of the PCR. The amplification 
efficiency was determined for both target and housekeeping genes and was equal (99–100%). 
 
PCR primers for mRNA amplification of the different selected genes were carefully designed 
using the web-based ProbeFinder software (Universal ProbeLibrary Design Center) [18] or via 
Roche Applied Science home page [19]. PCR primers have been positioned to span exon–intron 
boundaries, reducing the risk of detecting genomic DNA. Primers were purchased from 
Invitrogen™ (USA) and Roche (Mannheim, Germany). 
 
Suitable selection of housekeeping gene(s) was performed using Human Endogenous Control 
Gene Panel (TATAA Biocenter, Sweden). The Excel macro GeNorm VBA applet for Microsoft 
Excel was used to determine the gene(s) with most correlated expression in the set of samples. 
Homo sapiens HPRT (Hypoxanthine–guanine phosphoribosyltransferase) were used as internal 
control for blood, bone marrow, and cell-lines samples. Also housekeeping gene was used to 
verify integrity of RNA and efficacy of reverse transcription. Any specimen with inadequate 
HPRT mRNA was excluded from the study.  
Data analysis was performed with LigthCycler 480 Relative Quantification software (Roche, 
Mannheim, Germany). Relative levels of expression were calculated by the 2
−ΔΔCt
 method [20]. 
Each assay was done at least in triplicate and included marker-positive and marker-negative 
controls and reagent with no template controls. 
2.7. DNA sequencing 
At least one PCR product coming from each Real-time PCR experiment was used as template 
DNA. Products were purified by enzymatic method (ExoSAP-IT, Amersham USB). DNA 
sequencing was performed in a reference facility on ABI 3700 (Applied Biosystems) using Big 
Dye terminators. Forward and reverse primers used in sequencing reactions were the same as for 
the Real-time PCR, see Table 1. 
2.8. Statistical analysis 
Statistical significance of differences was evaluated at the 95% confidence level by non-
parametric statistic, Mann–Whitney U-test; p-value <0.05 were considered to be significant. 
Receiver operating characteristics (ROC) curve analysis was used to evaluate the diagnostic 
discrimination power of the selected differentially expressed genes. The threshold value for 
optimal sensitivity and specificity of PKP3 and AGR2 mRNA relative expression levels (R.E.L.) 
was also determined by ROC analysis. All of the statistical analyses were performed using the 
SPSS 12.0 for Windows. 
3. Results 
3.1. Search for gastrointestinal tumor-associated biomarkers using computational tools 
Digital differential display (DDD) data were used to identify and prioritize molecular markers 
highly expressed in GI cancers but absent in blood and bone marrow-derived libraries. The pools 
used in this analysis, their ID libraries and the ESTs clustered are shown in Table 2. Differential 
over representation were found for 34 genes in colorectal cancer libraries, for 96 in gastric cancer 
libraries, and for 144 in pancreatic cancer libraries in comparison with hematopoietic libraries. 
Potential up-regulated targets of note from this study include, among others, genes involved in cell 
adhesion and cytoskeleton, cell signaling, growth factor activity, ribosomal proteins, calcium-
related metabolism, heat shock proteins as well as hypothetical proteins. 
  
Table 2. Digital differential display: cDNA libraries: Pool of libraries, their identification numbers (IDs) and the expressed 
sequence tags (ESTs) clustered used in the digital differential display (DDD) bioinformatics tool 
Pool Lib (IDs) Clustered ESTs 
   
Colorectal cancer 842, 841, 840, 882, 1540, 988, 956, 987, 1447, 486 43918 
Gastric cancer 10324, 10311, 10310, 10306, 10325, 10302, 10301, 10299, 10305, 14437, 
1449, 721, 733 
44581 
Pancreatic cancer 1460, 5551, 9885, 721, 733 42014 
Blood and bone marrow 7038, 7037, 6976, 6975, 8975, 11923, 931, 5948, 5566, 9724, 8613, 14381, 
765 
51208 
   
 
From this set, we specifically selected those ESTs whose expression was at least 10-fold higher 
in each set of cancer libraries and undetectable or low represented in hematopoietic control 
libraries, defined as an expression count equal or less than four in DDD output. After these filters, 
we obtained a collection of 30, 58, and 91 genes in colon, gastric and pancreatic cancer-derived 
cDNA libraries, respectively (Fig. 1 and Table 3). 
 
 
 
Fig. 1. Overexpressed genes in colon, gastric and pancreatic cancer-derived cDNA libraries: Venn diagram showing 
overexpressed genes in colon, gastric and pancreatic cancer-derived cDNA libraries. Only those genes whose expression 
was at least 10-fold higher in each set of cancer libraries and undetectable or low represented in hematopoietic control 
libraries are shown. 
  
Table 3. Up-regulated genes in gastrointestinal tumors according to digital differential display (DDD) 
Gene name Gene Description UniGene # Function Folds 
EST 
counts in 
tumor 
libraries 
EST counts in 
hematopoietic 
libraries 
A: Colorectal 
 AGR2 
Anterior gradient 2 homolog 
(Xenopus laevis) 
Hs.226391 Secretory protein 14 42 3 
 ASS Argininosuccinate synthetase Hs.160786 Enzyme 24 24 0 
 CEACAM5 
Carcinoembryonic antigen-
related cell adhesión molecule 5 
Hs.220529 Receptor/surface/membrane 22 22 0 
 CLDN3 Claudin 3 Hs.25640 Receptor/surface/membrane 39 39 0 
 DIPA 
Hepatitis delta antigen-
interacting protein A 
Hs.66713 Binding protein 20 20 0 
 EFNB1 Ephrin-B1 Hs.144700 Binding protein 20 20 0 
 FLNB 
Filamin B, beta (actin binding 
protein 278) 
Hs.81008 Binding protein 26 26 1 
 GDF15 Growth differentiation factor 15 Hs.296638 Secretory protein 41 41 1 
 GMDS GDP-mannose 4,6-dehydratase Hs.105435 Enzyme 22 22 1 
 H1FX H1 histone family, member X Hs.75307 Binding protein 14 56 4 
 KLF5 Kruppel-like factor 5 (intestinal) Hs.84728 Binding protein 18 18 0 
 KRT18 Keratin 18 Hs.406013 Receptor/surface/membrane 42 126 3 
 KRT19 Keratin 19 Hs.309517 Receptor/surface/membrane 37 37 0 
 KRT8 Keratin 8 Hs.356123 Receptor/surface/membrane 78 78 1 
 LCN2 Lipocalin 2 (oncogene 24p3) Hs.204238 Secretory protein 19 19 0 
 LGALS4 
Lectin, galactoside-binding, 
soluble, 4 (galectin 4) 
Hs.5302 Binding protein 30 30 0 
 LOC374395 
Similar to RIKEN cDNA 
1810059G22 
Hs.381134 Hypothetical protein 21 21 0 
 MGC3047 Hypothetical protein Hs.76239 Hypothetical protein 25 25 1 
 MUC5B 
Mucin 5, subtype B, 
tracheobronchial 
Hs.103707 Secretory protein 24 24 0 
 PKP3 Plakophilin 3 Hs.148074 Receptor/surface/membrane 28 28 0 
 REG1A 
Regenerating islet-derived 1 
alpha (pancreatic stone protein, 
pancreatic thread protein) 
Hs.49407 Secretory protein 27 27 1 
 REG4 
Regenerating islet-derived 
family, member 4 
Hs.105484 Secretory protein 25 25 1 
 RHOB 
Ras homolog gene family, 
member B 
Hs.406064 Enzyme 29 29 1 
 S100A16 
S100 calcium binding protein 
A16 
Hs.8182 Binding protein 23 23 0 
 S100A6 
S100 calcium binding protein A6 
(calcyclin) 
Hs.275243 Binding protein 10 39 4 
 SAFB Scaffold attachment factor B Hs.23978 Binding protein 18 18 0 
 SLC39A8 
Solote carrier family 39 (zinc 
transporter), member 8 
Hs.284205 Zinc transporter 14 28 2 
 TACSTD1 
Tumor-associated calcium signal 
transducer 1 
Hs.692 Receptor/surface/membrane 19 19 0 
 WARP 
Von Willebrand factor A 
domain-related protein 
Hs.449009 Secretory protein 22 22 0 
 ZFP36L2 
Zinc finger protein 36, C3H 
type-like 2 
Hs.78909 Binding protein 12 25 2 
B: Gastric 
 A2M Alpha-2-macroglobulin Hs.74561 Binding protein 37 37 1 
 AGR2 
Anterior gradient 2 homolog 
(Xenopus laevis) 
Hs.226391 Secretory protein 35 106 3 
 ALDH1A1 
Aldehyde dehydrogenase 1 
family, member A1 
Hs.76392 Enzyme 11 44 4 
 ALDH3A1 
Aldehyde dehydrogenase 3 
family, member A1 
Hs.575 Enzyme 45 45 0 
 ANKRD9 Ankyrin repeat domain 9 Hs.432945 Binding protein 43 43 0 
 ATP1B1 
ATPase, Na+/K+ transporting, 
beta 1 polypeptide 
Hs.78629 Enzyme 25 25 0 
 CLDN4 Claudin 4 Hs.5372 Receptor/surface/membrane 27 27 1 
 CPA1 
Carboxypeptidase A1 
(pancreatic) 
Hs.2879 Enzyme 53 53 0 
 CPB1 Carboxypeptidase B1 (tissue) Hs.437028 Enzyme 20 20 0 
 CREB3L1 
cAMP responsive element 
binding protein 3-like 1 
Hs.405961 Biniding protein 22 22 0 
 CTRB1 Chymotrypsinogen B1 Hs.449833 Enzyme 29 29 0 
 DDX41 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 41 
Hs.274317 Binding protein 14 59 4 
 DECR2 
2,4-Dienoyl CoA reductase 2, 
peroxisomal 
Hs.15898 Enzyme 19 19 0 
 ELA3A 
Enastase 3A, pancreatic 
(protease E) 
Hs.471034 Enzyme 27 27 0 
 GLTSCR2 
Glioma tumor suppressor 
candidate region gene 2 
Hs.421907 Unknown function 11 47 4 
 GPX2 
Glutathione peroxidase 2 
(gastrointestinal) 
Hs.2704 Enzyme 21 21 0 
 GRN Granulin Hs.180577 Binding protein 29 29 1 
 ID1 
Inhibitor of DNA binding 1, 
dominant negative helix-loop-
helix protein 
Hs.410900 Binding protein 19 19 0 
 JARID1C 
Jumonji, AT-rich interactive 
domain 1C (RBP2-like) 
Hs.103381 Binding protein 27 27 1 
 KLF13 Kruppel-like factor 13 Hs.7104 Binding protein 18 18 0 
 KREMEN2 
Kringle containing 
transmembrane protein 2 
Hs.351474 Receptor/surface/membrane 25 25 0 
 KRT18 Keratin 18 Hs.406013 Receptor/surface/membrane 10 32 3 
 KRT19 Keratin 19 Hs.309517 Receptor/surface/membrane 21 21 0 
 KRT8 Keratin 8 Hs.356123 Receptor/surface/membrane 146 146 1 
 LDHA Lactate dehydrogenase A Hs.2795 Enzyme 17 383 22 
 LGALS4 
Lectin, galactoside-binding, 
soluble, 4 (galectin 4) 
Hs.5302 Binding protein 19 19 0 
 LISCH7 
Liver-specific bHLH-Zip 
transcription factor 
Hs.312129 Binding protein 22 22 1 
 LRFN4 
Leucine-rich repeat and 
fibronectin type III domain 
containing 4 
Hs.148438 Binding protein 43 43 1 
 LYZ Lysozyme (renal amyloidosis) Hs.234734 Enzyme 16 32 2 
 MEIS3 
Meis 1, myeloid ecotropic viral 
integration site 1 homolog 3 
(Mouse) 
Hs.380923 Binding protein 19 19 0 
 MUC1 Mucin 1, transmembrane Hs.89603 Secretory protein 26 26 0 
 MYEOV Myeloma overexpressed gene Hs.436000 Unknown function 21 21 0 
 MYH11 
Myosin, heavy polypeptide 11, 
smooth muscle 
Hs.78344 Binding protein 31 31 0 
 NQO1 
NAD(P)H dehydrogenase, 
quinone 1 (NQO1) 
Hs.406515 Enzyme 10 42 4 
 P4HB 
Procollagen-proline, 2-
oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase) 
Hs.410578 Binding protein 14 56 4 
 PGA5 Pepsinogen 5, group I Hs.432854 Enzyme 122 122 1 
 PGC Progastricsin (pepsinogen C) Hs.1867 Enzyme 95 95 0 
 PLK2 Polo-like kinase2 (Drosophila) Hs.398157 Enzyme 29 29 1 
 PME-1 
Protein phsphatase 
methylesterase-1 
Hs.63304 Enzyme 15 30 2 
 PNLIP Pancreatic lipase Hs.102876 Enzyme 20 20 0 
 PRSS2 Protease, serine, 2 (trypsine 2) Hs.511525 Enzyme 91 91 1 
 PYCR1 
Pyrroline-5-carboxylate 
reductase 1 
Hs.458332 Enzyme 11 71 6 
 REG1A 
Regenerating islet-derived 1 
alpha (pancreatic stone protein, 
pancreatic thread protein) 
Hs.49407 Secretory protein 55 55 1 
 REG1B 
Regenerating islet-derived 1 beta 
(pancreatic stone protein, 
pancreatic thread protein) 
Hs.4158 Secretory protein 23 23 0 
 REG4 
Regenerating islet-derived 
family, member 4 
Hs.105484 Secretory protein 68 68 1 
 RGS5 
Regulator of G-protein signalling 
5 
Hs.24950 Binding protein 30 30 0 
 S100A6 
S100 calcium binding protein A6 
(calcyclin) 
Hs.275243 Binding protein 11 44 4 
 SDC1 Syndecan 1 Hs.82109 Binding protein 13 27 2 
 SERPINB6 
Serine (or cysteine)proteinase 
inhibitor, clade B (ovalbumin), 
member 6 
Hs. 41072 Enzyme 13 27 2 
 SKB1 SKB1 homolog (S. pombe) Hs.367854 Binding protein 18 18 0 
 SPARCL1 SPARC-like 1 (mast9, Kevin) Hs.75445 Secretory protein 20 20 0 
 TACSTD1 
Tumor-associated calcium signal 
transducer 1 
Hs.692 Receptor/surface/membrane 29 29 0 
 TGFB1I4 
Transforming growth factor beta 
1-induced transcript 4 
Hs.114360 Secretory protein 23 23 1 
 THBS3 Thrombospondin 3 Hs.169875 Binding protein 20 20 0 
 TM4SF3 
Transmembrane 4 superfamily 
member 3 
Hs.84072 Receptor/surface/membrane 16 32 2 
 TRY2 Trypsin II precursor Hs.367767 Enzyme 24 24 0 
 WBSCR21 
Williams Beuren síndrome 
chromosome region 21 
Hs.182476 Binding protein 20 20 0 
 ZNF499 Zinc finger protein 499 Hs.445346 Binding protein 45 45 0 
C: Pancreatic 
 ABCD1 
ATP-binding cassette, sub-
family D (ALD), member 1 
Hs.159546 Binding protein 34 34 1 
 ADAM15 
A disintegrin and 
metalloproteinase domain 15 
(metargidin) 
Hs.312098 Enzyme 31 31 1 
 AGR2 
Anterior gradient 2 homolog 
(Xenopus laevis) 
Hs.226391 Secretory protein 42 127 3 
 AHSA1 
AHA1, activator of heat shock 
90 kDa protein ATPase homolog 
1 (yeast) 
Hs.204041 Enzyme 23 23 1 
 ALDH3A1 
Aldehyde dehydrogenase 3 
family, member A1 
Hs.575 Enzyme 85 85 0 
 APG4D 
APG4D autophagy 4 homolog D 
(S. cerevisiae) 
Hs.512799 Enzyme 52 52 0 
 ATAD3A 
ATPase family, AAA domain 
containing 3A 
Hs.467479 Enzyme 21 21 0 
 ATP1B1 
ATPase, Na+/K+ transporting, 
beta 1 polypeptide 
Hs.78629 Enzyme 23 23 0 
 C1S 
Complement component 1, s 
subcomponent 
Hs.458355 Enzyme 23 23 1 
 CAPN1 Calpain 1 (mu/I) large subunit Hs.356181 Enzyme 31 31 1 
 CCT7 
Chaperonin containing TCP1, 
subunit 7 (eta) 
Hs.368149 Binding protein 22 89 4 
 CDC42EP4 
CDC42 effector protein (Rho 
GTPase binding) 4 
Hs.3903 Binding protein 180 180 0 
 CLDN4 Claudin 4 Hs.5372 Receptor/surface/membrane 37 37 1 
 CPA1 
Carboxypeptidase A1 
(pancreatic) 
Hs.2879 Enzyme 55 55 0 
 CPB1 Carboxypeptidase B1 (tissue) Hs.437028 Enzyme 28 28 0 
 CRABP2 
Cellular retinoic acid binding 
protein 2 
Hs.183650 Binding protein 21 21 0 
 CTRB1 Chymotrypsinogen B1 Hs.74502 Enzyme 18 18 0 
 CTSD 
Cathepsin D (lysosomal aspartyl 
protease) 
Hs.34375 Enzyme 10 31 3 
 DHRSX 
Dehydrogenase/reductase (SDR 
family) X-linked 
Hs.11779 Enzyme 53 53 0 
 DKK3 
Dickkopf homolog 3 (Xenopus 
laevis) 
Hs.130865 Secretory protein 99 99 0 
 DLGAP4 
Discs, large (Drosophila) 
homolog-associated protein 4 
Hs.249600 Binding protein 18 36 2 
 DRAP1 
DR1-associated protein 1 
(negative cofactor 2 α) 
Hs.356742 Binding protein 24 24 1 
 EEF1A2 
Eukaryotic translation elongation 
factor 1 alpha 2 
Hs.433839 Binding protein 59 59 0 
 EGLN2 Egl nine homolog 2 (C. elegans) Hs.324277 Binding protein 29 29 0 
 EIF4G1 
Eukaryotic translation initiation 
factor 4 gamma, 1 
Hs.433750 Binding protein 13 26 2 
 ELA3A 
Enastase 3A, pancreatic 
(protease E) 
Hs.471034 Enzyme 33 33 0 
 ELF3 
E74-like factor 3 (ets domain 
transcription factor, ephitelial 
specific) 
Hs.67928 Binding protein 20 20 1 
 EPHA2 EphA2 Hs.171596 Receptor/surface/membrane 19 19 0 
 FKBP4 FK506 binding protein 4, 59 kDa Hs.848 Binding protein 31 63 2 
 FLJ23322 Hypothetical protein Hs.387601 Hypothetical protein 58 58 1 
 FLNB 
Filamin B, beta (actin binding 
protein 278) 
Hs.81008 Binding protein 30 30 1 
 FLNC 
Filamin C, gamma (actin binding 
protein 280) 
Hs.58414 Binding protein 67 67 0 
 GCG Glucagon Hs.423901 Enzyme 74 74 0 
 GSN 
Gelsolin (amyloidosis, Finnish 
type) 
Hs.446537 Binding protein 10 30 3 
 HAS3 Hyaluronan synthase 3 Hs.85962 Enzyme 23 23 1 
 HMGA1 High mobility group AT-hook 1 Hs.57301 Binding protein 21 108 5 
 IDS 
Iduronate 2-sulfatase (Hunter 
syndrome) 
Hs.303154 Enzyme 21 21 0 
 IFI27 
Interferon, alpha-inducible 
protein 27 
Hs.278613 Receptor/surface/membrane 25 25 1 
 IGFBP6 
Insulin-like growth factor 
binding protein 6 
Hs.274313 Binding protein 22 22 0 
 ITGB4 Integrin, beta 4 Hs.85266 Cell adhesion molecules 19 19 0 
 ITGB6 Integrin, beta 6 Hs.57664 Cell adhesion molecules 23 23 0 
 JUP Junction plakoglobin Hs.2340 Cell adhesion molecules 57 57 1 
 KRT13 Keratin 13 Hs.433871 Receptor/surface/membrane 28 28 0 
 KRT17 Keratin 17 Hs.2785 Receptor/surface/membrane 37 112 3 
 KRT18 Keratin 18 Hs.406013 Receptor/surface/membrane 116 349 3 
 KRT19 Keratin 19 Hs.309517 Receptor/surface/membrane 163 163 0 
 KRT5 Keratin 5 Hs.433845 Receptor/surface/membrane 79 79 0 
 KRT6A Keratin 6A Hs.367762 Receptor/surface/membrane 37 37 0 
 KRT7 Keratin 7 Hs.23881 Receptor/surface/membrane 39 79 2 
 KRT8 Keratin 8 Hs.356123 Receptor/surface/membrane 223 223 1 
 KRTHB1 Keratin, hair, Basic, 1 Hs.170925 Receptor/surface/membrane 34 34 1 
 LAMC2 Laminin, gamma 2 Hs.54451 Cell adhesion molecule 27 27 0 
 LCN2 Lipocalin 2 (encogen 24p3) Hs.204238 Secretory protein 55 55 0 
 LOC142678 Skeletrophin Hs.135805 Binding protein 41 41 1 
 LRP1 
Low density lipoprotein-related 
protein 1(alpha-2-macroglobulin 
receptor) 
Hs.162757 Receptor/surface/membrane 13 27 2 
 LUM Lumican Hs.406475 Binding protein 10 63 6 
 LY6E 
Lymphocyte antigen 6 complex, 
locus E 
Hs.77667 Receptor/surface/membrane 21 42 2 
 MGAT4B 
Mannosyl (alpha-1,3)-
glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, 
isoenzyme B 
Hs.437277 Enzyme 69 69 0 
 MGC10471 Hypothetical protein Hs.24998 Hypothetical protein 109 109 1 
 MGC2776 Hypothetical protein Hs.335550 Hypothetical protein 49 49 0 
 MGLL Monoglyceride lipase Hs.409826 Enzyme 21 21 1 
 MRPL49 
Mitochondrial ribosomal protein 
L-49 
Hs.75859 Ribosomal protein 11 59 5 
 MRPS12 
Mitochondrial ribosomal protein 
S12 
Hs.411125 Ribosomal protein 23 23 0 
 MUC5B 
Mucin 5, subtype B, 
tracheobronchial 
Hs.103707 Secretory protein 34 34 0 
 NID Nidogen (enactin) Hs.356624 Binding protein 82 82 1 
 NRBP Nuclear receptor binding protein Hs.272736 Binding protein 16 50 3 
 NUMBL 
Numb homolog (Drosophila)-
like 
Hs.326953 Unknown function 20 20 0 
 P4HB 
Procollagen-proline, 2-
oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase) 
Hs.410578 Enzyme 14 57 4 
 PAK4 
p21 (CDKN!A)-activated kinase 
4 
Hs.20447 Binding protein 26 26 0 
 PCBD 
6-Pyruvoyl-tetrahydropterin 
synthase/dimerization cofactor of 
hepatocyte nuclear factor 1 alpha 
(TCF1) 
Hs.3192 Enzyme 33 33 1 
 PCQAP 
PC2 (positive cofactor 2, 
multiprotein complex) 
glutamina/Q-rich-associated 
protein 
Hs.410347 
Transcription regulatory 
protein 
21 43 2 
 PKP3 Plakophilin 3 Hs.148074 Receptor/surface/membrane 23 23 0 
 PLAT Plasminogen activator, tissue Hs.274404 Enzyme 32 32 1 
 PLEC1 
Plactin 1, intermediate filament 
binding protein 500 kDa 
Hs.79706 Binding protein 40 40 1 
 PNLIP Pancreatic lipase Hs.102876 Enzyme 24 24 0 
 PRSS2 Protease, serine, 2 (trypsin 2) Hs.511525 Enzyme 94 94 1 
 PRSS3 Protease, serine, 3 (mesotrypsin) Hs.435699 Enzyme 31 31 1 
 RAC1 
Ras-related C3 botulinum toxin 
substrate 1 (rho family, small 
GTP binding protein Rac1) 
Hs.413812 Binding protein 18 73 4 
 REG1A 
Regenerating islet-derived 1 
alpha (pancreatic stone protein, 
pancreatic thread protein) 
Hs.49407 Secretory protein 46 46 1 
 REG1B 
Regenerating islet-derived 1 beta 
(pancreatic stone protein, 
pancreatic thread protein) 
Hs.4158 Secretory protein 24 24 0 
 RGS19IP1 
Regulador of G-protein 
signalling 19 interacting protein 
1 
Hs.6454 Receptor/surface/membrane 12 24 2 
 SCD 
Stearoyl-CoA desaturase (delta-
9-desaturase) 
Hs.119597 Enzyme 29 59 2 
 SCNN1A 
Sodium channel, nonvoltage-
gated 1 alpha 
Hs.446415 Binding protein 22 22 0 
 SDC1 Syndecan 1 Hs.82109 Receptor/surface/membrane 12 24 2 
 SERPINA1 
Serine (or cysteine) proteinase 
inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), 
member 1 
Hs.297681 Enzyme 26 26 0 
 SFRP2 
Secreted frizzled-related protein 
2 
Hs.31386 Secretory protein 29 29 0 
 SSFA2 Sperm specific antigen 2 Hs.438599 Receptor/surface/membrane 41 41 0 
 STMN3 Stathmin-like 3 Hs.285753 Binding protein 12 63 5 
 SUGT1 
SGT1, supressor of G2 allele of 
SKP1 (S. cerevisiae) 
Hs.107776 Binding protein 24 24 1 
 TIMM50 
Translocase of inner 
mitochondrial membran 50 
homolog (yeast) 
Hs.355819 Enzyme 17 51 3 
 TMEPAI 
Transmembrane, prostate 
androgen-induced RNA 
Hs.83883 Unknown function 20 40 2 
       
 
Hits (known ESTs) showing ≥10-fold differences in the tumor-derived libraries in comparison with normal blood and bone 
marrow tissue-derived cDNA libraries are shown: colorectal (A), gastric (B) and pancreatic (C). Gene name, gene 
description, gene function and UniGene number of each hit are also shown. EST counts in tumors and hematopoietics 
libraries are shown. The last column of the tables indicates the number of fold differences in the gastrointestinal tumor-
derived libraries in comparison with normal tissue-derived cDNA libraries. When EST counts in hematopoietics libraries 
were zero, EST counts in tumors are considered as fold difference. 
Among all of the up-regulated genes obtained, we identified several known genes which have 
previously been shown to be overexpressed in gastrointestinal tumors, and proposed as 
micrometastasis markers [21] as keratins 8, 18, and 19, CEACAM5, and tumor-associated calcium 
signal transducer 1 (TACSTD1). The tissue distribution and tumor specificity were analyzed using 
representation profiles obtained with virtual northern (Table 4). Based on in silico data we could 
predict that some of the markers could be expressed in the hematopoietic compartment. 
  
Table 4. Expression of selected markers in gastrointestinal cancers, bone marrow and white blood cells: EST and SAGE data 
 
Colon cancer  Gastric cancer  Pancreatic cancer  Bone marrow  Blood 
 
EST Data SAGE data  EST data SAGE data  EST data SAGE data  
EST 
data 
SAGE 
data 
 SAGE data 
              
PKP3 35/170084 27/643586  11/70532 74/448716  23/75487 13/189999  0/44611 0/282890  4/846268 
AGR2 90/151938 45/643586  117/65595 342/448716  133/74783 36/189999  3/44571 0/282890  0/846268 
LCN2 48/170084 53/643586  17/70532 165/448716  60/75487 213/189999  2/44611 90/282890  2/846268 
EFNB1 30/170084 21/643586  1/70532 28/448716  9/75487 7/189999  0/44611 2/282890  11/846268 
ASS1 62/170084 147/643586  17/70532 41/448716  20/75487 16/189999  0/44611 0/282890  3/846268 
LGALS4 93/170084 56/643586  18/70532 232/448716  8/75487 46/189999  0/44611 0/282890  1/846268 
MGC3047 1/170084 0/643586  2/70532 9/448716  6/75487 8/189999  0/44611 0/282890  0/846268 
CLDN3 152/170084 80/643586  6/70532 96/448716  1/75487 29/189999  0/44611 0/282890  7/846268 
S100A16 46/170084 164/643586  5/70532 73/448716  20/75487 66/189999  2/44611 0/282890  1/846268 
S100A6 65/151938 506/643586  49/65595 656/448716  68/74783 480/189999  3/44571 77/282890  625/846268 
GNT-V 4/151938 2/643586  1/65595 0/448716  0/74783 0/189999  0/44571 0/282890  0/846268 
EGFR 7/151938 1/643586  3/65595 2/448716  0/74783 0/189999  0/44571 0/282890  0/846268 
              
 
Each column represents the number of ESTs or SAGE tags corresponding to the gene divided by the total number of ESTs 
or SAGE tags in all libraries with the given tissue/histology. Only SAGE data are available for white cells blood. PKP3, 
plakophilin 3; AGR2, anterior gradient homolog 2; LCN2, lipocalin 2 (oncogene 24p3); EFNB1, ephrin-B1; ASS1, 
argininosuccinate synthetase; LGALS4; lectin, galactoside-binding, soluble, 4 (galectin 4); MGC3047, hypothetical 
protein, MXRA8; CLDN3, claudin 3; S100A16, S100 calcium binding protein A16; S100A6, S100 calcium binding protein 
A6 (calcyclin); GNT-V, beta-1,6-N-acetylglucosaminyltransferase V, MGAT 5; EGFR, epidermal growth factor receptor. 
3.2. Experimental validation of the in silico data: qRT-PCR in cell lines 
Criteria to select molecular markers identified by bioinformatic approach for quantitative real-
time PCR studies are described in “Section 2.1”. In brief, we select those novel markers with 
absent or low expression in blood and bone marrow-derived EST libraries and high expression in 
gastrointestinal cancer-derived EST libraries. In addition functional annotations based on Gene 
Ontology and related with epithelial cellular components or (potentially) with metastatic process 
[22] were taken into account. 
 
In this way, we chose PKP3, AGR2, LCN2, S100A16, S100A6, EFNB1, ASS1, LGALS4, 
MGC3047/MXRA8, and CLDN3 for further experimental validation. 
 
Interestingly PKP3, LGALS4, CLDN3, and EFNB1 were involved in cell adhesion, following 
biological process annotations in Gene Ontology. S100A6 and S100A16 are related in calcium-
dependent protein binding. ASS1 has argininosuccinate synthase activity. No significantly 
overrepresented GO annotations were found for AGR2, LCN2 and MGC3047/MXRA8. 
 
The expression of these selected markers was compared against EGFR and GNT-V, both 
described as overexpressed in gastrointestinal cancer. The expression levels of these genes were 
measured in 10 gastrointestinal tumor cell-lines (eight colorectal tumor cell-lines, one 
gastroesophageal cell-line, and one pancreatic cell-line). The values obtained were compared 
against three hematopoietic tumor cell-lines (Jurkat, K562, and KG1) and three different pools of 
normal bone marrow that include 23 individual samples. All selected genes assessed showed 
higher expression levels in gastrointestinal tumor cell-lines than in normal human bone marrow 
with two exceptions, LCN2 and MGC3047 (Fig. 2). LCN2 showed lower expression levels in all 
gastrointestinal tumor cell-lines tested than normal human bone marrow. MGC3047 only showed 
higher expression levels over to those obtained with normal human bone marrow in OJC1 
pancreatic tumor cell-line. The rest of the markers showed high expression in at least 7–10 
gastrointestinal tumor cell-lines than in normal human bone marrow. Also, S100A16 was the 
unique marker assessed that showed higher expression levels than normal human bone marrow in 
all tumor cell-lines tested. Although GNT-V was expressed in 8 out of 10 cell digestive cancer 
cell-lines, its values were together with LCN2, EFNB1, ASS1, and MGC3047, the ones that 
showed the lowest expression in the tumor cell-lines assessed and they were not selected for blood 
mRNA quantification. 
 
 
 
Fig. 2. Expression profile in cell-lines and normal human bone marrows: heat-map showing relative 
mRNA expression of in silico selected genes (rows) in cell-lines and bone marrow (columns). mRNA 
relative expression were measured by qRT-PCR. Results are the mean of at least three independent 
measurements. Data were normalized vs. the values obtained in human normal bone marrow. Relative 
expression levels are shown in a color scale. Genes are described in Table 3. Cell-lines (columns) are as 
shown: colorectal cancer (Gp5d, LoVo, DLD1, LS513, HT29, OJC4, OJC5, OJC6); gastric 
adenocarcinoma (OE19); pancreatic carcinoma (OJC1); hematopoietic (Jurkat, KG1 and K562); normal 
human bone marrows (BM). *Indicated those genes selected for their mRNA quantification in blood 
samples from patients. 
Among all the genes assessed, PKP3, AGR2, S100A16, S100A6, LGALS4, and CLDN3 
showed the most highly expression values with regard to normal human bone marrow. 
  
3.3. mRNA quantitative detection of selected genes in peripheral blood from patients with 
gastrointestinal cancer and controls 
We chose PKP3, AGR2, S100A6, S100A16, LGALS4, and CLDN3 for mRNA quantitative 
detection in peripheral blood samples from gastrointestinal cancer patients and controls. All of 
them showed an expression up to 10
2
- to 10
5
-fold higher in tumor cell-lines than in normal human 
bone marrow. Also, EGFR mRNA expression was measured in blood samples in order to compare 
their results with those obtained with the mRNA markers selected. All of these were expressed in 
at least 8 out of 10 tumor cell-lines. 
 
Among the six potential molecular markers assessed in-patient and matched control blood 
samples, PKP3 and AGR2 showed the most remarkable results (Table 5 and Fig. 3). Values for 
PKP3 and AGR2 mRNA were significantly higher in blood samples from gastrointestinal cancer 
patients than in blood samples from non-carcinoma patients with a significant level of p = 0.000 
and 0.019, respectively (Mann–Whitney U-test). 
Table 5. Median relative expression levels and ratios of candidate mRNA markers of circulating tumor cells in patients and 
controls blood 
Gene name Gene symbol Patients blood Controls blood Patients: controls 
     
Plakophilin 3 PKP3 175.42 9.32 18.82 
Anterior gradient 2 AGR2 13.50 0 * 
Claudin 3 CLDN3 8040.27 29,299 2.74 
Galectin 4 LGALS4 27,073 13,070 2.07 
S100 calcium binding protein A6 (calcyclin) S100A6 53,840 58548.6 0.92 
S100 calcium binding protein A16 S100A16 41,945 23,090 1.82 
Epidermal growth factor receptor EGFR 67.22 24.64 2.72 
     
 
mRNA levels were measured by qRT-PCR as described in Section 2. Results are the mean of at least three independent 
measurements. *There was no AGR2 expression in normal bloods. 
  
 
 
 
Fig. 3. mRNA expression levels of PKP3, AGR2, LGALS4, CLDN3, S100A6, S100A16 and EGFR mRNA in peripheral 
blood: mRNA expression levels of PKP3, AGR2, LGALS4, CLDN3, S100A6, S100A16 and EGFR mRNA (Y-axis) 
determined in peripheral blood from non-carcinoma patients (C) and patients (P) with gastrointestinal cancer (X-axis). 
mRNA levels were measured by qRT-PCR as described in Section 2. Results are the mean of at least three independent 
measurements. 
ROC curve analysis showed that the area under the ROC curve for PKP3 mRNA relative 
expression levels was 1.00 (S.E. = 0.00; p = 0.002). Optimal sensitivity (100%) and specificity 
(100%) was obtained by applying 56.61 as a PKP3 mRNA R.E.L. cutoff value. 
 
In the case of AGR2, ROC curve analysis showed that the area under the ROC curve for AGR2 
mRNA relative expression levels was 0.864 (S.E. = 0.092; 95% confidence range 0.683–1.045; 
p = 0.023). Optimal sensitivity (72.7%) and specificity (100%) was obtained by applying 0.044 as 
AGR2 mRNA R.E.L. cutoff value. In both cases, the calculated cutoff value may be useful to 
define positive or negative results and it discriminates samples of peripheral blood from patients 
with gastrointestinal cancer and control donors. 
 
Area under the ROC curve for EGFR mRNA relative expression levels was 0.564 
(S.E. = 0.151; 95% confidence range 0.268–0.859; p = 0.692). Thus, in our series, EGFR mRNA 
amplification was not useful to differentiate between carcinoma patients and controls. In relation 
to the other four potential molecular markers assessed, S100A6, S100A16, LGALS4, and CLDN3, 
neither of them could be considered specific enough to detect circulating tumor cells. Perhaps 
increasing the number of samples analyzed and ROC curve analysis, or using logistic regression to 
determine a combination equation using all six molecular markers assessed could yield a stronger 
and powerful diagnostic discrimination test. 
 
PKP3 and AGR2 seem to be two new promising molecular markers for qRT-PCR detection of 
circulating tumor cells in peripheral blood samples from gastrointestinal cancer patients. Our 
findings had improved the previous results obtained with other common markers, widely used in 
micrometastasis detection, such as EGFR. 
  
3.4. mRNA detection of selected genes in colon cancer samples 
To validate the DDD data and the results obtained in cell-lines, we further investigated the 
mRNA expression of the genes PKP3, AGR2, LGALS4, and CLDN3 in colon cancer samples. 
These genes exhibited up-regulated expression based on both in silico data and GI cancer cell-lines 
qRT-PCR results. Absolute quantification by real-time RT-PCR analysis using RNA isolated from 
FFPE was used. Patient samples included primary colon tumors (n = 14). In addition 
metachronous metastatic lesions (hepatic and peritoneal) excised from two of these patients were 
studied. 
 
Among all of the markers tested, CLDN3 showed expression in a large number of tissues 
analyzed (90.9%) followed by AGR2 (81.8%), LGALS4 (45.4%), and PKP3 (40%). For PKP3, 
there was no concordant mRNA expression between primary and metastasis in the cases studied, 
suggesting a dynamic regulation of their expression during tumor progression. 
4. Discussion 
Metastatic hematogenous spreading is one of the most important factors affecting the prognosis 
of carcinoma patients, including gastrointestinal cancer. Detection of carcinoma cells in the blood 
or minimal deposits in distant organs as bone marrow could be important to identify patients at 
high risk of relapse or disease progression [7]. PCR amplification of tissue or tumor-selective 
mRNA is the most powerful tool for surrogate detection of this isolated tumor cells. However, 
specificity of different mRNA-based assays has been controversial and there is a need for a 
systematic evaluation for each new biomarker proposed. 
 
Our research aimed to identify, at first, a set of specific epithelial gene markers highly 
expressed in gastrointestinal cancer. Electronic databases analysis allowed us to obtain a list of 
genes that are differentially expressed, to the point of statistical significance, in colon, pancreas, 
and gastric libraries. We hypothesized that these transcripts could represent the molecular 
signature associated with CTC. Global gene expression profile of cancer cells isolated from blood 
has been recently described in colon, breast, and prostatic tumors, using an immunomagnetic 
enrichment and microarray analysis [23]. In a recent report, Solmi et al. [24] have used a 
microarray-based high-throughput screening method to identify candidate marker mRNAs for 
CTC detection. However, employing a conventional RT-PCR procedure they could not find a set 
of suitable and consistent mRNA marker for detection of colonic cells in the blood. In previous 
reports using both in silico data-mining tools and conventional RT-PCR, these authors [25] 
suggest that among 15 genes differentially expressed in colon, only non-SMC structural 
maintenance of chromosomes, element 1 protein (NSE1) and gastrin (GAS) mRNAs could be 
suitable for detection of circulating colon cancer cells in blood. 
 
To point out the validity of our results using an in silico approach, our set of overexpressed 
genes included different markers previously used for CTC detection. In addition, AGR2 and 
different S100 proteins were identified in our work as well as in the CTC molecular profile 
proposed by Smirnov et al. [23]. 
 
To obtain independent evidence to support the bioinformatics-approach for selecting CTC 
markers, quantitative mRNA expression of selected genes were analyzed in gastrointestinal cell-
lines, hematopoietic cell-lines, and normal bone marrows. In order to validate their usefulness as 
potential molecular markers for gastrointestinal disseminated tumor cell detection, these results 
were compared with those obtained for EGFR and GNT-V. 
 
Among all the genes assessed, PKP3, AGR2, S100A16, S100A6, LGALS4, and CLDN3 
showed the most highly expressed values with regard to normal human bone marrow. For this 
reason they were chosen for further analysis for their expression in blood from gastrointestinal 
cancer patients and controls. One of the main problems with any mRNA-based assays is the 
illegitimate transcription of the so-called “epithelial specific transcripts” in hematopoietic 
compartment [2]; [3] ;  [4]. In our study, we included a quantitative RT-PCR approach and a 
significant number of controls samples (23 bone marrows and 10 bloods) in order to select the 
most specific mRNA markers. 
 
In patient blood samples, qRT-PCR for PKP3 and AGR2 showed the most promising results. 
We could calculate an mRNA R.E.L. cutoff value of 56.61 and 0.044 for PKP3 and AGR2, 
respectively. These cut-off points may be useful to distinguish between samples of peripheral 
blood from gastrointestinal cancer patients and control samples. However, we need to underscore 
that all of the patients included in our series of blood samples were in advanced disease status. To 
better evaluate the predictive and prognostic role (if any) of PKP3 and AGR2 qRT-PCR assays in 
blood, a prospective study with a larger number, and less advanced, cancer patients are clearly 
needed. 
 
When we compared our results obtained for PKP3 and AGR2 with those obtained for EGFR, 
our findings suggest that PKP3 and AGR2 could be better for its use as surrogate markers for 
circulating tumor cells detection in patients with GI cancer. 
 
This is the first time that PKP3, a member of the p120ctn/plakophilin subfamily of armadillo 
proteins, is suggested as a molecular marker for CTC detection. PKP3 is present in desmosomes of 
epithelial cells and binds all three desmogleins, desmocollin, plakoglobin, desmoplakin, and the 
epithelial keratin 18. This protein not only functions in desmosome-dependent cell adhesion, but in 
signaling transduction [26]; [27] ;  [28]. 
 
In view of the importance of β-catenin and other armadillo proteins in tumor biology, it is 
surprising that up to now, knowledge about the occurrence of PKPs in tumors is limited and little 
is known about their possible biologic role in tumor invasion and metastasis [29]. Recent studies 
had shown evidences that PKP3 protein may serve as useful marker for predicting the clinical 
outcome of head and neck tumors [30] and non-small cell lung cancer [31]. Other investigators 
[32] had demonstrated that this protein is highly expressed in various types of adenocarcinomas 
(colorectal, pancreatic, and prostate). In our work, PKP3 mRNA was highly expressed in digestive 
cancer cell-lines (8/10) but less in colon cancer samples (40%). One limitation of our analysis was 
the use of RNA isolated from FFPE. Recently, we studied PKP3 protein by immunohistochemistry 
in a large set of digestive tumors and found its expression in 66.7% of cases [33]. Aigner et al. 
have shown that PKP3 is repressed in the epithelial to mesenchymal transition of tumors under 
control by the E-cadherin repressor ZEB1 [34]. These data suggest, as previously stated [23] that 
gene expression signatures of CTCs may change as the disease progresses. In addition, selective 
suppression of gene transcription was one of the characteristics of the molecular signature 
associated with bone marrow micrometastasis in breast cancer [35]. 
 
In relation with AGR2, the human homolog of Xenopus anterior gradient 2 (XAG2), our 
results corroborated and complemented a previous study in which it has been postulated as a 
marker for detection of circulating tumor cells in peripheral blood of advanced cancer patients 
[23]. AGR2 mRNA is expressed in several normal human tissue types that are rich in epithelial 
cells, including colon, pancreas, lung, stomach, rectum, prostate, and breast [36]; [37] ;  [38]. 
AGR2 has been demonstrated to be up-regulated not only in hormonal-dependent tumors as breast, 
endometrial, renal, and prostate cancers but also in lung carcinomas [39]. Using qRT-PCR 
analysis, we demonstrated an increased AGR2 expression in gastrointestinal cancer cell-lines and 
colon tumors. Although AGR2 function is not known, experimental data suggest that it could act 
as a survival factor through inhibition of p53, and enhancing tumor cell adhesion to substratum 
[40] ;  [41]. 
  
However, identification of truly specific markers is a difficult task. Our quantitative RT-PCR 
assay demonstrated background expression in blood derived from non-tumor donors for S100A16, 
S100A6, LGALS4, and CLDN3. Although these gene transcripts were found highly expressed in 
cancer specimens, none of them could be considered specific enough, at first, for circulating 
epithelial cells detection. Their value in multigene qRT-PCR approach as a discrimination test 
could be analyzed using logistic regression and ROC curve. 
 
In conclusion, novel and known gastrointestinal-specific mRNA markers for circulating tumor 
cells have been identified through in silico analysis and validated in clinical material. Our results 
indicate that quantitative real-time reverse transcription-PCR assay targeted to PKP3 and AGR2 
mRNAs might be helpful to detect circulating tumor cells in patients with gastrointestinal cancer. 
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